Literature DB >> 9482270

Neuroleptics and dopamine transporters.

T A Reader1, A R Ase, N Huang, C Hébert, N M van Gelder.   

Abstract

The effects of neuroleptic treatments on dopamine transporters and on dopamine receptors was investigated in the forebrain of adult rats treated for 21 days with either haloperidol, clozapine or saline. The dopamine D1 receptors, labeled with [3H]SCH23390, increased in nucleus accumbens, latero-dorsal rostral neostriatum and substantia nigra, after clozapine but not haloperidol. The dopamine D2 receptors, studied with [3H]raclopride, increased in nucleus accumbens and in dorso-lateral, ventro-medial and dorso-medial quadrants of the rostral neostriatum after either haloperidol or clozapine treatments, and also in latero-ventral rostral neostriatum but only after haloperidol. Haloperidol also up-regulated D2 receptors in rostral and caudal neostriatum, but clozapine produced a more uneven increase, especially in caudal neostriatum. In contrast, the densities of dopamine uptake sites, or transporters, labeled with [125I]RTI-121, remained unchanged after both neuroleptic treatments. The observation that dopamine transporters are resistant to treatments that modify D1 and D2 receptors indicates that these uptake sites can probably be ruled out as the target of neuroleptic drugs, and that dopamine receptor up-regulations can indeed occur independently of the densities of nerve endings at the terminal fields of innervation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9482270     DOI: 10.1023/a:1022405621365

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  37 in total

1.  D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics.

Authors:  L Farde; F A Wiesel; A L Nordström; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brain and to induce stereotyped behavior.

Authors:  M E Reith; B E Meisler; H Sershen; A Lajtha
Journal:  Biochem Pharmacol       Date:  1986-04-01       Impact factor: 5.858

3.  D-1 dopamine receptors in the rat brain: autoradiographic localization using [3H]SCH 23390.

Authors:  T M Dawson; D R Gehlert; H I Yamamura; A Barnett; J K Wamsley
Journal:  Eur J Pharmacol       Date:  1985-02-05       Impact factor: 4.432

Review 4.  Dopamine transporter: biochemistry, pharmacology and imaging.

Authors:  M J Kuhar; P M Sanchez-Roa; D F Wong; R F Dannals; D E Grigoriadis; R Lew; M Milberger
Journal:  Eur Neurol       Date:  1990       Impact factor: 1.710

5.  Quantitative autoradiographic localization of the D1 and D2 subtypes of dopamine receptors in rat brain.

Authors:  S J Boyson; P McGonigle; P B Molinoff
Journal:  J Neurosci       Date:  1986-11       Impact factor: 6.167

6.  Sodium-sensitive cocaine binding to rat striatal membrane: possible relationship to dopamine uptake sites.

Authors:  L T Kennedy; I Hanbauer
Journal:  J Neurochem       Date:  1983-07       Impact factor: 5.372

7.  Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis.

Authors:  G Chouinard; J L Vainer; M C Bélanger; L Turnier; P Beaudry; J Y Roy; R Miller
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1994-11       Impact factor: 5.067

8.  Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats.

Authors:  R E See; A W Toga; G Ellison
Journal:  J Neural Transm Gen Sect       Date:  1990

Review 9.  Clozapine and D1/D2 antagonism in extrapyramidal functions.

Authors:  J Gerlach; L Hansen
Journal:  Br J Psychiatry Suppl       Date:  1992-05

10.  Autoradiographic visualization of dopamine D-2 receptors in the monkey brain using the selective benzamide drug [3H]raclopride.

Authors:  C Köhler; A C Radesäter
Journal:  Neurosci Lett       Date:  1986-05-06       Impact factor: 3.046

View more
  7 in total

1.  Nico M. van Gelder, the inquisitive neurochemist.

Authors:  A Hamberger; T A Reader
Journal:  Neurochem Res       Date:  1999-11       Impact factor: 3.996

2.  Striatal presynaptic dopamine in schizophrenia, Part I: meta-analysis of dopamine active transporter (DAT) density.

Authors:  Paolo Fusar-Poli; Andreas Meyer-Lindenberg
Journal:  Schizophr Bull       Date:  2012-01-26       Impact factor: 9.306

3.  Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait.

Authors:  Jose J Mateos; Francisco Lomeña; Eduard Parellada; Font Mireia; Emili Fernandez-Egea; Javier Pavia; Alberto Prats; Francisca Pons; Miquel Bernardo
Journal:  Psychopharmacology (Berl)       Date:  2006-09-22       Impact factor: 4.530

4.  Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism.

Authors:  Jose J Mateos; Francisco Lomeña; Eduardo Parellada; Mireia Font; Emili Fernandez; Javier Pavia; Alberto Prats; Francisca Pons; Miquel Bernardo
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

5.  Cocaine upregulates the dopamine transporter in fetal rhesus monkey brain.

Authors:  Y Fang; O K Ronnekleiv
Journal:  J Neurosci       Date:  1999-10-15       Impact factor: 6.167

6.  Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1.

Authors:  K Van Laere; L De Ceuninck; R Dom; J Van den Eynden; H Vanbilloen; J Cleynhens; P Dupont; G Bormans; A Verbruggen; L Mortelmans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-03       Impact factor: 9.236

7.  Altered levels of dopamine transporter in the frontal pole and dorsal striatum in schizophrenia.

Authors:  Hirotaka Sekiguchi; Geoff Pavey; Brian Dean
Journal:  NPJ Schizophr       Date:  2019-12-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.